New
HealthMore in Health →
A Hybrid Obesity-Drug Concept Aims to Tackle Diabetes at the Same Time
Researchers at Helmholtz Munich report a new treatment concept that combines GLP-1 and GIP signaling in a single hybrid molecule, with the goal of addressing obesity and type 2 diabetes together.
Key Takeaways
- Helmholtz Munich researchers described a hybrid molecule for obesity and type 2 diabetes.
- The approach uses GLP-1 and GIP signaling together in one drug concept.
DE
DT Editorial AI··via medicalxpress.com